Company Overview
| Stock Name | Fusen Pharm |
|---|---|
| Stock Code | 01652 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 從事研發、生產及銷售多種用以治療感冒及發熱、心血管疾病及貧血的中成藥及西藥產品,核心產品為雙黃連類感冒藥。 |
| Listing Date | 2018-07-11 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 河南省淅川縣城區工業園區 |
| Business Address (Hong Kong) | 香港灣仔告士打道56號東亞銀行港灣中心29樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.fusenyy.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 2.08 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | RMB 0.01 / shares |
| Offer Period | 2018-06-28 to 2018-07-04 |
| Global Offering Shares | 200,000,000 shares |
| HK Public Offer Shares (Initial) | 20,000,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 180,000,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 800,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 416,000,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 704.9M |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +1278% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 2,000,000,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣97.1百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 45,600,000 |
| Listing Expenses / Funds Raised | ~10.96% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2015 | 2016 | 2017 |
|---|---|---|---|
| Revenue | 368,634 | 441,988 | 452,580 |
| Cost of sales | -195,357 | -219,799 | -200,634 |
| Gross profit | 173,277 | 222,189 | 251,946 |
| Other income and gains, net | 3,251 | 10,888 | 5,918 |
| Selling and distribution expenses | -63,636 | -74,208 | -90,704 |
| Administrative expenses | -26,039 | -40,277 | -44,980 |
| Operating profit | 86,853 | 118,592 | 122,180 |
| Net finance costs | -29,585 | -3,824 | -5,844 |
| Profit before tax | 57,268 | 114,768 | 116,336 |
| Income tax expense | -11,233 | -18,570 | -19,285 |
| Profit for the year | 46,035 | 96,198 | 97,051 |
| Profit attributable to owners | 44,879 | 95,073 | 96,820 |
Balance Sheet
| Item | 2015 | 2016 | 2017 |
|---|---|---|---|
| Cash and cash equivalents | 32,569 | 244,390 | 474,621 |
| Trade and bills receivables | 208,800 | 123,027 | 109,115 |
| Inventories | 106,633 | 100,779 | 100,506 |
| Total current assets | 1,156,165 | 944,910 | 752,749 |
| Total assets | 1,361,477 | 1,151,088 | 951,220 |
| Total current liabilities | 1,016,807 | 994,628 | 731,978 |
| Total liabilities | 1,167,282 | 1,024,479 | 768,443 |
| Total equity | 194,195 | 126,609 | 182,777 |
| Equity attributable to owners | 189,583 | 121,065 | 180,565 |
| Interest-bearing borrowings | 766,262 | 600,678 | 391,600 |
Cash Flow Statement
| Item | 2015 | 2016 | 2017 |
|---|---|---|---|
| Net cash from operating activities | 69,804 | 172,345 | 133,206 |
| Net cash from investing activities | 67,185 | 327,666 | 455,514 |
| Net cash from financing activities | -131,625 | -288,190 | -358,370 |
| Net increase in cash | 5,364 | 211,821 | 230,350 |
| Depreciation of PP&E | 14,946 | 15,045 | 15,996 |
| Amortisation of intangible assets | 117 | 200 | 200 |
| Purchase of PP&E | -27,837 | -19,977 | -4,410 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 2.54 |
|---|---|
| First Day Open | HK$ 2.33 |
| First Day Change | 22.12% |
| First Day Volume | 72934000.0 |
| First Day Turnover | 180523000.0 |
| Use of Proceeds | 1、約30%或112.4百萬港元將用于擴充計劃;
2、約10%或37.4百萬港元將用于產品廣告及營銷;
3、約10%或37.4百萬港元將用于擴展現有營銷及分銷網絡,以提高市場滲透水平,覆蓋更多最終客戶,從而增加市場占有率;
4、約10%或37.4百萬港元將用于繼續進行研究及開發活動,尤其是為與外部合作伙伴合作進行的研究項目提供資金;
5、約15%或56.1百萬港元將用于并購治療領域與我們目前重點治療領域類似的中成藥飲片及顆粒劑或其他西藥生產商,以拓展產品組合及增強競爭優勢;
6、約15%或56.1百萬港元將用作收購中成藥或其他西藥的生產許可證,以拓展產品組合;
7、約10%或約37.4百萬港元將用于為營運資金及其他一般企業用途提供資金。 |
Underwriting Syndicate
Sole Sponsor (1)
中信建投(国际)融资有限公司 CE BAU112
Overall Coordinators (3)
Joint Bookrunners (6)
Joint Lead Managers (6)
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 曹長城 | — |
| Company Secretary | 梁偉峰 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 曹長城先生透過Full Bliss、Rayford及致凱持有487,200,000股,佔緊隨全球發售完成後已發行股本60.90%;Full Bliss及Rayford各持有180,180,000股(22.52%);曹篤篤先生透過致凱持有126,840,000股(15.86%);華潤醫藥基金持有60,000,000股(7.50%);第一聯雅及林曉波先生持有39,960,000股(5.00%)。 |
|---|




